Abstract:The therapeutic limitations such as insufficient efficacy, drug resistance, metastasis, and undesirable side effects are frequently caused by the long duration monotherapy based on chemotherapeutic drugs. multiple combinational anticancer strategies such as nucleic acids combined with chemotherapeutic agents, chemotherapeutic combinations, chemotherapy and tumor immunotherapy combinations have been embraced, holding great promise to counter these limitations, while still taking including some potential risks. Nowadays, an increasing number of research has manifested the anticancer effects of phytochemicals mediated by modulating cancer cellular events directly as well as the tumor microenvironment. Specifically, these natural compounds exhibited suppression of cancer cell proliferation, apoptosis, migration and invasion of cancer cells, P-glycoprotein inhibition, decreasing vascularization and activation of tumor immunosuppression. Due to the low toxicity and multiple modulation pathways of these phytochemicals, the combination of chemotherapeutic agents with natural compounds acts as a novel approach to cancer therapy to increase the efficiency of cancer treatments as well as reduce the adverse consequences. In order to achieve the maximized combination advantages of small-molecule chemotherapeutic drugs and natural compounds, a variety of functional nano-scaled drug delivery systems, such as liposomes, host-guest supramolecules, supramolecules, dendrimers, micelles and inorganic systems have been developed for dual/multiple drug co-delivery. These co-delivery nanomedicines can improve pharmacokinetic behavior, tumor accumulation capacity, and achieve tumor site-targeting delivery. In that way, the improved antitumor effects through multiple-target therapy and reduced side effects by decreasing dose can be implemented. Here, we present the synergistic anticancer outcomes and the related mechanisms of the combination of phytochemicals with small-molecule anticancer drugs. We also focus on illustrating the design concept, and action mechanisms of nanosystems with co-delivery of drugs to synergistically improve anticancer efficacy. In addition, the challenges and prospects of how these insights can be translated into clinical benefits are discussed.

Drug Combination in Clinical Cancer Treatments

Anticancer Drug Combinations, How Far We Can Go Through?

Searching Synergistic Dose Combinations for Anticancer Drugs

Anticancer drug combinations : The next medical challenge

Molecular-targeted agents combination therapy for cancer: developments and potentials

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Effective drug combinations in breast, colon and pancreatic cancer cells

Combination antitumor therapy with targeted dual-nanomedicines

Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination – An effective strategy to improve clinical treatment

An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations

Advances in computational approaches in identifying synergistic drug combinations.

Drug-herb combination therapy in cancer management

Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research

Anticancer drugs: How to select small molecule combinations?

Rational combinations of targeted cancer therapies: background, advances and challenges

Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer

Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy

Recent Advances of Cocktail Chemotherapy by Combination Drug Delivery Systems.

Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment